DTL
TBPH icon

Dynamic Technology Lab’s Theravance Biopharma TBPH Stock Holding History

Dynamic Technology Lab’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,007
Closed -$130K – 1032
2015
Q2 		$130K Buy
+10,007
New +$155K 0.05% 678

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return

Dynamic Technology Lab's TBPH Position: Q3 2015 in Review

Dynamic Technology Lab sold out of Theravance Biopharma (TBPH) in Q3 2015, closing a stake of 10,007 shares — an estimated $130K sold.

Dynamic Technology Lab first reported a position in TBPH in Q2 2015 and held it in 1 quarter. The position peaked at $130K in Q2 2015. 83 funds tracked by Wall St. Rank hold TBPH as of Q3 2015.

  • Dynamic Technology Lab reported no remaining Theravance Biopharma position as of Q3 2015 after selling out during the quarter.
  • Dynamic Technology Lab sold 10,007 Theravance Biopharma shares in Q3 2015, an estimated $130K.
  • Dynamic Technology Lab first reported a position in Theravance Biopharma in Q2 2015 and held it in 1 quarter.
  • Dynamic Technology Lab's Theravance Biopharma position peaked at $130K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2015.

Based on Dynamic Technology Lab's 13F filing for Q3 2015, filed 16 Nov 2015.